Delivering novel,
targeted inhalation
therapies to improve
the lives of patients
suffering from serious
orphan lung diseases.

Learn More

Insmed and ARIKACE are registered trademarks in the United States and various other countries.

ARIKACE^®:

a novel inhalation therapy
designed to improve the
efficacy, safety, and
convenience of treatment.

Late-stage clinical trials are
underway in the US and Europe
as we prepare for regulatory filings
and commercialization.

• About Our Clinical Trials
  for CF Pseudomonas Patients
• About Our Clinical Trials
  for NTM Patients

Administered once daily
using an optimized
eFlow® Electronic Nebulizer
(PARI Pharma GmbH).*

*In the US and Canada, Investigational eFlow® Nebulizer System (PARI Respiratory Equipment, Inc.)

70%of Adult
CF Patients have acquired serious
chronic Pseudomonas
lung infections.

Once-a-day ARIKACE treatment
in development.

• ARIKACE for CF
  Pseudomonas Patients
• About Our Clinical Trials

Administered once daily
using an optimized
eFlow® Electronic Nebulizer
(PARI Pharma GmbH).*

*In the US and Canada, Investigational eFlow® Nebulizer System (PARI Respiratory Equipment, Inc.)

Chronic, debilitating
NTM lung infections
are on the rise,
with no approved inhaled
antibiotics available.

Once-a-day ARIKACE treatment
in development.

• ARIKACE for NTM
• About Our Clinical Trials

Administered once daily
using an optimized
eFlow® Electronic Nebulizer
(PARI Pharma GmbH).*

*In the US and Canada, Investigational eFlow® Nebulizer System (PARI Respiratory Equipment, Inc.)